Frag 17-23 Peptide

$70.00

High-purity TB-500 Fragment 17-23 (sequence: LKKTETQ), a synthetic heptapeptide corresponding to residues 17-23 of thymosin beta-4, supports advanced pre-clinical investigations into actin-binding mechanisms, cytoskeletal dynamics, and regenerative signaling pathways. Investigators utilize this compound to examine actin sequestration, cell migration promotion, and tissue remodeling processes in cellular and animal models. National Science Labs provides TB-500 Fragment 17-23 exclusively for laboratory research exploring actin-interaction motifs, wound healing dynamics, and anti-inflammatory responses in controlled experimental contexts.

Out of stock

For Research Use Only — Not for Human Consumption
 

Free shipping on all orders over $200 (US)

  • 99% Purity – Third-Party Tested
  • Fast & Reliable Shipping
Guaranteed Checkout

Researchers employ TB-500 Fragment 17-23 to investigate its conserved LKKTETQ motif, which retains actin-binding capability from the parent thymosin beta-4 protein. Pre-clinical observations in cell culture and dermal models indicate modulation of actin polymerization, enhancement of cellular motility, and support for tissue reorganization processes.

This truncated peptide facilitates focused examination of cytoskeletal regulation, angiogenic signaling contributions, and regenerative responses without the full-length protein’s broader interactions.

Scientific Overview of TB-500 Fragment 17-23 Applications

Pre-clinical models demonstrate the fragment’s retention of key functional attributes:

  • Binding to actin via the LKKTETQ motif, regulating cytoskeletal dynamics and supporting cell migration in wound healing assays. https://pubmed.ncbi.nlm.nih.gov/10030854/
  • Promotion of tissue remodeling through modulation of actin polymerization and cellular reorganization in dermal repair systems.
  • Attenuation of inflammatory responses in stress-induced cellular models, contributing to reduced pro-inflammatory signaling.
  • Support for angiogenic pathway activation and vascular repair mechanisms in relevant tissue contexts.
  • Examination of reduced mast cell activation potential compared to full-length thymosin beta-4 in immune-related studies.
  • Investigation of regenerative signaling contributions in musculoskeletal and epithelial injury paradigms.

For further details on thymosin beta-4 fragments, actin-binding peptides, and regenerative mechanisms in pre-clinical research, refer to the Peptide Sciences or About Peptides sections.

Why Investigators Select National Science Labs TB-500 Fragment 17-23

National Science Labs manufactures TB-500 Fragment 17-23 under stringent GMP-compliant protocols to ensure batch-to-batch consistency and reliability for pre-clinical experiments. Independent third-party testing verifies each lot for:

  • Purity ≥99.9% by HPLC
  • Structural identity confirmation via mass spectrometry
  • Complete Certificate of Analysis (CoA) documentation provided per batch

For Research Use Only. This product is supplied exclusively for in vitro and in vivo pre-clinical research by qualified investigators. Statements about this peptide have not been evaluated by the FDA.

Initiate Your TB-500 Fragment 17-23 Research Protocol

Source high-purity TB-500 Fragment 17-23 from current limited batches to ensure optimal stability and performance in actin-binding and tissue remodeling studies.

Additional information

Weight.125 lbs
Dimensions9 × 7 × .5 in

Keep lyophilized peptides sealed in their original vial, protected from light and humidity, and store at -4°F or colder for optimal long-term stability in research settings; short-term refrigeration at around 39°F suffices for immediate use within weeks, though freezer storage maximizes integrity across extended research timelines.